Pharma Focus Asia
KP - Choose our fully recyclable blister films

The Real Cost of Poor Data Integrity in Pharmaceutical Manufacturing: A Lachman White Paper


Every business faces risk. Broadly speaking, the primary categories of business risk are Market, Financial, Execution, and Regulatory. Successful companies have developed a core competency in managing for these risks, turning risk management into a sustainable competitive advantage. For drug manufacturers, recent trends have underscored the importance of managing Regulatory risk in order to remain a viable business. More specifically, these trends have raised the profile of Data Integrity (“DI”).


This white paper highlights the cost of reactive regulatory compliance is daunting, and erodes credibility with customers, employees, reduces time to market and limits future strategic options. It also elucidates the risks of non?compliance increase with the number of NDAs/ANDAs and facilities, as increased scrutiny comes with scale, and regulatory authorities are willing to send warnings to multiple sites based on the review of one site. This study serves as a pharmaceutical manufacturer’s number one lever to pull to reduce risk of regulatory action is in improving Data Integrity. Doing so may provide a sustainable advantage in a highly competitive market.

This white paper also lists recommended practices to improve data integrity in a healthcare facility like—proactive working with outside specialists to educate company and site leadership, along with all site personnel, on their responsibilities and the need for absolute personal accountability in ensuring integrity of practices, data, records, and documentation, making sure you have sufficient knowledgeable GMP/QA and supervisory personnel. One manager overseeing 200 scientists just won’t do. This white paper also recommends the creation and enforcement of a company-wide standard for data integrity and the ethical behaviour required to follow such standards, and provide expert training to affect these standards. Lastly, continuously and rigorously auditing actual performance against integrity standards for the systems, procedures, controls, and documentation practices that assure the reliability of data, records, and their documentation, is highly recommended.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024